Scientific Program – EmbryologyFriday, November 13 only |
 |
Friday, November 13
| 08:30-10:00 | AI AND AUTOMATION IN IVF LABORATORY | HALL B |
| Capsule | A recent RCT by Illingworth et al et al (Nature Medicine 2024) was unable to demonstrate non-inferiority of a deep learning algorithm compared with standard morphology. Although no harm in using AI selection was proven, AI -based solutions need to demonstrate improvement in time, quality, and safety in IVF laboratory procedures, without compromising clinical outcomes, while reducing cost, before widespread adoption | |
| Chairpersons | Rita Vassena, Spain Miguel Gallardo, Portugal |
|
| 08:30-09:00
0830 |
Debate: Does AI improve embryo selection in IVF Pro: AI can improve embryo selection Giovanni Coticchio, Italy |
|
| 09:00-09:25 |
AI in sperm selection: Difficult cases and proxy molecular markers |
|
| 09:25-09:30 | Discussion | |
| 09:30-0955 |
Automation in lab work in IVF – how far did we get? Do we still need an embryologist? |
|
| 09:55-10:00 | Discussion | |
| 10:00-10:30 | Coffee break, visit the exhibition and e-poster viewing |
| 10:30-12:00 | VITRIFICATION | HALL B |
| Capsule | Shorter vitrification and warming protocols are becoming more common for embryos, while still lagging somewhat behind oocytes. New approaches are being considered that challenge our understanding of cryobiology, and new media are being developed to improve results. | |
| Chairpersons | Helen Picton, UK | |
| 10:30-10:55 |
Shorter protocols of vitrification and warming for oocytes |
|
| 10:55-11:00 | Discussion | |
| 11:00-11:25 |
Simplified vitrification and warming methods: Redefining efficiency in oocyte and embryo cryopreservation |
|
| 11:25-11:30 | Discussion | |
| 11:30-11:55 |
Is direct warming of embryos the new revolution? |
|
| 11:55-12:00 | Discussion | |
| 12:00-12:05 | Change of session |
| 12:05-12:30 | PLENARY SESSION | HALL A Streamed to all halls |
| Capsule | ||
| Chairpersons | ||
| 12:05-12:30 |
PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc) |
|
| 12:35-13:35 | Industry supported session – Hall A Industry supported session – Hall B |
| 13:35-14:30 | Lunch break, visit the exhibition and e-poster viewing |
| 14:30-15:30 | IVM AND IMMATURE OOCYTES | HALL B |
| Capsule | In vitro maturation has by now proven safe and effective on a per-oocyte basis, although clinical adoption seems to be lagging. The efficiency of controlled ovarian hyperstimulation however, clashes with the comfort of patients and the increase in cost of the procedure (drugs, anesthetic services, recovery time, etc..). Is there a place for true IVM in standard clinical practice? | |
| Chairpersons | Alessandro Bartolacci, Italy Ioannis Sfontouris, Greece |
|
| 14:30-15:00
14:30 |
Debate: This house believes that “true” IVM should be part of the toolkit of every clinic Pro: IVM should be indicated for certain patients |
|
| 15:00-15:25 |
In vitro derived oocytes: from research to clinical application |
|
| 15:25-15:30 | Discussion | |
| 15:30-15:35 | Change of session |
| 15:35-17:00 | QUO VADIS PGT-A? | HALL B |
| Capsule | In spite of the clear results from 2 non-selection studies, some questions still persist in the PGT-A world. We are debating advances and limitations of this technology, and look at future developments in the field. PGT-P for polygenic is a controversial technique that uses scores to estimate embryos risk to develop adults diseases like diabetes to select those with lower risk | |
| Chairpersons | Helen Picton, UK Giovanni Coticchio, Italy |
|
| 15:35-16:05
15:35 |
Debate: Should we report mosaicism in PGT-A? Yes, we should: Darren Griffen, UK |
|
| 16:05-16:25 |
When PGT-M is needed, should we test also for aneuploidy |
|
| 16:25-16:30 | Discussion | |
| 16:30-16:55 |
PGT-P: The future of PGT or an unethical approach? |
|
| 16:55-17:00 | Discussion | |
| 17:00-17:20 | Coffee break, visit the exhibition and e-poster viewing |
| 17:20-18:30 | AN EMBRYO IS AN EMBRYO IS AN EMBRYO? | HALL B |
| Capsule | From choosing the best day to transfer to the developmental potential of nonconventional fertilized oocytes, this session will challenge some long held beliefs and present new evidence for | |
| Chairpersons | Rita Vassena, Spain Mina Popovic, Spain |
|
| 17:20-17:40 |
1PN, 2.1PN, 3PN: When to rescue and when to discard? |
|
| 17:40-18:00 |
Are embryos better nurtured in utero or in vitro? A comparison of day 3 vs day 5 transfer, including a cost-effectiveness perspective |
|
| 18:00-18:20 |
How to care for the embryo in challenging laboratory settings |
|
| 18:20-18:30 | Q&A | |
